Highlights from ASCO GU 2024

home / data-dialogue-with-the-oncology-brothers / highlights-from-asco-gu-2024

Following ASCO GU 2024, Tian Zhang, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to review recent data in patients with genitourinary cancers.

Rohit Gosain, MD; Rahul Gosain, MD; and Tian Zhang, MD, presenting slides

EP. 1: CONTACT-02: Cabozantinib Plus Atezolizumab in mCRPC

Rohit Gosain, MD;Rahul Gosain, MD;Tian Zhang, MD
February 8th 2024

Following ASCO GU 2024, Tian Zhang, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from CONTACT-02 investigating cabozantinib plus atezolizumab in metastatic castration-resistant prostate cancer.

Rohit Gosain, MD; Rahul Gosain, MD; and Tian Zhang, MD, presenting slides

EP. 2: BRCAAway: Novel Hormonal Therapies With PARP inhibitors in mCRPC

Rohit Gosain, MD;Rahul Gosain, MD;Tian Zhang, MD
February 8th 2024

Tian Zhang, MD, and the Oncology Brothers discuss the BRCAAway trial, which is investigating abiraterone, olaparib, or the combination in patients with metastatic castration-resistant prostate cancer.

Rohit Gosain, MD; Rahul Gosain, MD; and Tian Zhang, MD, presenting slides

EP. 3: AMBASSADOR: Adjuvant Pembrolizumab in Muscle-Invasive Urothelial Carcinoma

Rohit Gosain, MD;Rahul Gosain, MD;Tian Zhang, MD
February 8th 2024

A review of interim findings from the AMBASSADOR study looking at adjuvant pembrolizumab in patients with muscle-invasive urothelial carcinoma.

Rohit Gosain, MD; Rahul Gosain, MD; and Tian Zhang, MD, presenting slides

EP. 4: Overall Survival Update for KEYNOTE-564 in Renal Cell Carcinoma

Rohit Gosain, MD;Rahul Gosain, MD;Tian Zhang, MD
February 8th 2024

Tian Zhang, MD, and the Oncology Brothers offer comprehensive insights on the overall survival update for KEYNOTE-564 in renal cell carcinoma.